Posted by Michael Wonder on 20 Jun 2026
Mounjaro rejection explains why our access to cheaper medicines if failing
20 June 2026 - The rejection by one of the world’s biggest pharmaceutical companies of Australia’s proferred bargain over the blockbuster drug Mounjaro was dramatic and scathing.
When Eli Lilly walked away from listing its GLP-1 drug on the PBS, the company was determined to make its reasons glaringly public.
